Since their initial explosion onto the market, there is a growing pipeline demonstrating the promise of aptamer therapeutics across…

The passing of the FDA Modernization Act 2.0 is a commitment to reducing the use of animals in drug testing. The act allows researchers to use…

DNA day on April 25th, celebrates major scientific achievements concerning DNA, in particular the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix…

New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…

  Biologics, such as antibody therapeutics have revolutionised our approach to the treatment of disease. Therapeutic antibodies have become the predominant class of drugs in the development pipeline and the…

Gene therapy is the future for the treatment of several, often life-threatening conditions. Several gene therapy assets are currently under trial targeting cancers, sensory organs, blood disease, and rare…

Virus mediated gene therapy has emerged as a powerful and promising option for the treatment of various diseases such as metabolic, cardiovascular, muscular, hematologic, ophthalmologic, and infectious diseases and…

Prostate cancer is the most common cancer among men, with approximately 1.1 million new cases diagnosed per year worldwide. Most cancer-related deaths are caused by metastases in vital organs,…

The blood-brain barrier (BBB) is a highly specialized network of blood vessels that effectively separates the brain environment from the circulatory system. Delivering drugs into the brain environment has…

CRISPR/Cas9 therapeutics have been in vitro techniques historically. This review shows the promise of potential in vivo aptamer-based delivery of CRISPR/Cas9 therapeutics. Precise editing of DNA sequences in the human genome…